A Phase 1 interventional study of Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 5mg Tirzepatide by subcutaneous injection on upper arm.
Drug: Tirzepatide
Participants received 5mg Tirzepatide by subcutaneous injection on thigh.
Drug: Tirzepatide
Participants received 5mg Tirzepatide by subcutaneous injection on abdomen.
Drug: Tirzepatide
Tirzepatide administered SC
Also known as: LY3298176
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞])
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC\[0-∞\]) was evaluated.
Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose
PK: Maximum Concentration (Cmax) of Tirzepatide
PK: Maximum Concentration (Cmax) of Tirzepatide was evaluated.
Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 18 | 18 | 18 |
| Received at least one dose of study drug | 18 | 18 | 18 |
| Completed | 18 | 18 | 18 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 18 | 18 | 18 |
| Received at least one dose | 18 | 18 | 18 |
| Completed | 18 | 18 | 18 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 18 | 18 | 18 |
| Received at least one dose | 18 | 17 | 18 |
| Completed | 18 | 17 | 18 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC\[0-∞\]) was evaluated.
| Hour * nanogram per milliliter (h*ng/mL) | Tirzepatide - Abdomen | Tirzepatide - Upper Arm | Tirzepatide - Thigh |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞]) | 112000 ± 24 | 111000 ± 21 | 106000 ± 22 |
PK: Maximum Concentration (Cmax) of Tirzepatide was evaluated.
| Nanogram per Millilitre (ng/mL) | Tirzepatide - Abdomen | Tirzepatide - Upper Arm | Tirzepatide - Thigh |
|---|---|---|---|
| PK: Maximum Concentration (Cmax) of Tirzepatide | 603 ± 25 | 556 ± 23 | 520 ± 21 |
Collected over Up to 36 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirzepatide - Abdomen | 0/54 (0%) | 0/54 (0%) | 37/54 (68.5%) |
| Tirzepatide - Upper Arm | 0/54 (0%) | 0/54 (0%) | 31/54 (57.4%) |
| Tirzepatide - Thigh | 0/53 (0%) | 0/53 (0%) | 23/53 (43.4%) |
| Event | Tirzepatide - Abdomen | Tirzepatide - Upper Arm | Tirzepatide - Thigh |
|---|---|---|---|
| NauseaGastrointestinal disorders | 20/54 | 12/54 | 11/53 |
| Decreased appetiteMetabolism and nutrition disorders | 13/54 | 7/54 | 3/53 |
| HeadacheNervous system disorders | 12/54 | 8/54 | 6/53 |
| DyspepsiaGastrointestinal disorders | 10/54 | 11/54 | 6/53 |
| Abdominal distensionGastrointestinal disorders | 8/54 | 10/54 | 8/53 |
| VomitingGastrointestinal disorders | 9/54 | 10/54 | 4/53 |
| ConstipationGastrointestinal disorders | 4/54 | 2/54 | 2/53 |
| EructationGastrointestinal disorders | 3/54 | 4/54 | 1/53 |
| Early satietyGeneral disorders | 2/54 | 0/54 | 3/53 |
| DiarrhoeaGastrointestinal disorders | 3/54 | 2/54 | 1/53 |
All randomized participants.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 47.1 ± 12.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 17 |
| Male | 37 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 16 |
| Not Hispanic or Latino | 38 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 14 |
| White | 40 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 54 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Apr 2020, 6 months.
Results were first posted in Mar 2023, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide